Artificial intelligence applications continue to expand in biotech, addressing challenges from open-access publishing to clinical research design. Researchers developed an AI platform capable of identifying questionable open-access journals with 75% accuracy, potentially streamlining quality control in scientific publishing. Concurrently, clinical trial review firm Advarra unveiled an AI-powered protocol optimization tool, using its vast operational dataset to enhance trial design efficiency and reduce site burden. These innovations exemplify AI’s growing role in improving research transparency and execution.